JAK inhibitors use in immune-mediated inflammatory diseases not tied to thromboembolic risk

Written By : Aditi

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-05-31 03:15 GMT | Update On 2023-05-31 09:19 GMT

An article published in Rheumatology has concluded that JAK inhibitors are not tied to an increased risk of thromboembolic than placebo in immune-mediated inflammatory diseases or IMIDs patients.

Based on Preliminary data, clinicians have been warned regarding the increased venous thrombotic risk associated with using JAK inhibitors (JAKi).

This was further investigated by researchers in the present study using databases from MEDLINE and EMBASE.

The study summary includes the following essential considerations:

There were 19443 patients in the JAKi group and 6354 in the control group.
In the JAKi and control group, Thirty-one and 20 events were reported.
The mean follow-up duration was of 16.8 weeks.
There was no thromboembolic risk among IMIDs patients treated with JAKi compared to placebo.

They said, “JAKi do not increase thromboembolic risk in IMIDs patients.”

The study limitations were related to the non-reporting of cardiovascular events and underestimation.

Further reading:

Francesco Campanaro and others, Venous and arterial thromboembolic risk of JAK inhibitors: a systematic review with meta-analysis, Rheumatology, 2023; kead211, https://doi.org/10.1093/rheumatology/kead211

Article Source : Rheumatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Aditi

Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

New EASO guidance recommends semaglutide and tirzepatide as first-line treatments for obesity and its major complications

2025-10-06 03:00 GMT

JAK inhibitors use in immune-mediated inflammatory diseases not tied to thromboembolic risk

Similar News

Sugar-Free Chewing Gum Shows Potential for Thirst Relief Among Maintenance Hemodialysis Patients, Finds Study

Vildagliptin-Dapagliflozin FDC Effective in High CV Risk Indian T2DM Patients: Findings from Latest DAa-ViNCI Study

Sibutramine-Topiramate Combo Effective for Long-Term Weight Loss in Obesity: Study Finds

New EASO guidance recommends semaglutide and tirzepatide as first-line treatments for obesity and its major complications

GLP-1 Drugs Cut Heart Risks in Overweight Diabetics, Safeguard Kidneys for All: JAMA

Rapid test for influenza viruses: Simply taste your way to infection

Inflammation Markers Help Predict AKI After Bladder Cancer Surgery, reports study

GLP-1RAs Show Promise for Kidney Protection in Type 2 Diabetes, Reveals Research